KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.

doi:10.1084/jem.20192205

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.

The Journal of experimental medicine - 6 Jul 2020

Janardhan Harish Palleti, Meng Xiuling, Dresser Karen, Hutchinson Lloyd, Trivedi Chinmay M

Abstract excerpt

Human hepatic vascular cavernomas, the most common benign tumor of the liver, were described in the mid-1800s, yet the mechanisms for their formation and effective treatments remain unknown. Here, we demonstrate gain-of-function mutations in KRAS or BRAF genes within liver endothelial cells as a causal mechanism for hepatic vascular cavernomas. We identified gain-of-function mutations in KRAS or BRAF genes in...

Topics

Adherens Junctions
Adult
Aged, 80 and over
Animals
Cell Communication
Embryo Loss
Endothelial Cells
Female
Gain of Function Mutation
Humans
Liver

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Macrophages

Male

Mice

Middle Aged

Mitogen-Activated Protein Kinases

Mutation

Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 32405640
DOI: 10.1084/jem.20192205
PMCID: PMC7336315

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.PMID 32405640Read ↗

Frequent GNAQ and GNA14 Mutations in Hepatic Small Vessel Neoplasm.Semantic proximity Read ↗

PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism.Semantic proximity Read ↗

Genetic Basis and Therapies for Vascular Anomalies.Semantic proximity Read ↗

Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling.Semantic proximity Read ↗

Cutaneous and hepatic vascular lesions due to a recurrent somatic GJA4 mutation reveal a pathway for vascular malformationSemantic proximity Read ↗

Vascular malformations: An overview of their molecular pathways, detection of mutational profiles and subsequent targets for drug therapySemantic proximity Read ↗

Genetic Causes of Vascular Malformations and Common Signaling Pathways Involved in Their Formation.Semantic proximity Read ↗

Somatic Loss-of-Function PIK3R1 and Activating Non-hotspot PIK3CA Mutations Associated with Capillary Malformation with Dilated Veins (CMDV)Semantic proximity Read ↗

Trametinib as a promising therapeutic option in alleviating vascular defects in an endothelial KRAS-induced mouse model.Semantic proximity Read ↗

Molecular landscape and classification of vascular anomalies.Semantic proximity Read ↗

Targeted Therapies for Slow‐Flow Vascular MalformationsSemantic proximity Read ↗

GNA14 and GNAQ somatic mutations cause spinal and intracranial extra-axial cavernous hemangiomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.